Literature DB >> 16607622

Interference of programmed electromagnetic stimulation with pacemakers and automatic implantable cardioverter defibrillators.

Marianne Gwechenberger1, Friedrich Rauscha, Günter Stix, Gernot Schmid, Jeanette Strametz-Juranek.   

Abstract

A commercially available magnetic therapy system, designed for clinical application as well as for private use without medical supervision, was examined with respect to its potential for causing electromagnetic interference with implantable pacemakers (PMs) and automatic implantable cardioverter defibrillators (AICDs). A sample of 15 PMs and 5 AICDs were experimentally investigated. Each of the implants was realistically positioned in a homogeneous, electrically passive torso phantom and exposed to the magnetic fields of the system's applicators (whole body mat, cushion, and bar applicator). The detection thresholds of the implants were programmed to maximum sensitivity and both unipolar as well as bipolar electrode configurations were considered. The evaluation of possible interferences was derived from the internal event storages and pacing statistics recorded by the implants during exposure. Any "heart activity" recorded by the implants during exposure was interpreted as a potential interference, because the implant obviously misinterpreted the external interference signal as a physiological signal. Only cases without any recorded "heart activity" and with nominal pacing rates (as expected from the program parameter settings) of the implants were rated as "interference-free." Exposure to the whole body mat (peak magnetic induction up to 265 microT) did not show an influence on PMs and AICD in any case. The cushion applicator at the highest field intensity (peak magnetic induction up to 360 microT) led to atrial sensing defects in four PM models with unipolar electrode configuration. Under bipolar electrode configuration no disturbances occurred. The bar applicator led to sensing problems and consecutively reduced pacing rates in all tested PM models under unipolar electrode configuration and maximum field intensity (peak magnetic induction up to 980 microT). Bipolar electrode configuration resolved the problem. The investigated AICDs did not show malfunctions under any investigated condition. In conclusion, the examined PEMF therapy system did not interfere with the investigated implantable cardiac devices with bipolar electrode configuration. However, unipolar electrode configuration in pacemakers seems to be potentially hazardous during application of the examined PEMF therapy system.

Entities:  

Mesh:

Year:  2006        PMID: 16607622     DOI: 10.1002/bem.20217

Source DB:  PubMed          Journal:  Bioelectromagnetics        ISSN: 0197-8462            Impact factor:   2.010


  5 in total

1.  Implantable cardioverter defibrillator and 50-Hz electric and magnetic fields exposure in the workplace.

Authors:  M Souques; I Magne; J Lambrozo
Journal:  Int Arch Occup Environ Health       Date:  2010-11-11       Impact factor: 3.015

Review 2.  [Pulsed electromagnetic fields (PEMF)--results in evidence based medicine].

Authors:  Karin Pieber; Othmar Schuhfried; Veronika Fialka-Moser
Journal:  Wien Med Wochenschr       Date:  2007-01

Review 3.  Pulsed electromagnetic fields: promising treatment for osteoporosis.

Authors:  T Wang; L Yang; J Jiang; Y Liu; Z Fan; C Zhong; C He
Journal:  Osteoporos Int       Date:  2019-01-02       Impact factor: 4.507

4.  Therapeutic use of pulsed electromagnetic field therapy reduces prostate volume and lower urinary tract symptoms in benign prostatic hyperplasia.

Authors:  Marta Tenuta; Maria G Tarsitano; Paola Mazzotta; Livia Lucchini; Franz Sesti; Giorgio Fattorini; Carlotta Pozza; Valerio Olivieri; Fabio Naro; Daniele Gianfrilli; Andrea Lenzi; Andrea M Isidori; Riccardo Pofi
Journal:  Andrology       Date:  2020-03-16       Impact factor: 3.842

Review 5.  Wireless Wearables and Implants: A Dosimetry Review.

Authors:  Katrina Guido; Asimina Kiourti
Journal:  Bioelectromagnetics       Date:  2019-12-18       Impact factor: 1.848

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.